Filing Details

Accession Number:
0001127602-16-054884
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-06-07 12:56:11
Reporting Period:
2016-06-03
Filing Date:
2016-06-07
Accepted Time:
2016-06-07 12:56:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1613103 Medtronic Plc MDT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1341125 Richard Kuntz 710 Medtronic Pkwy Ms Lc300
Minneapolis MN 55432
Srvp & Chief Scien, Clin, Reg No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2016-06-03 23,028 $47.77 127,647 No 4 M Direct
Ordinary Shares Acquisiton 2016-06-03 35,872 $36.24 163,519 No 4 M Direct
Ordinary Shares Disposition 2016-06-03 49,905 $82.60 113,614 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (Right to Buy) Disposition 2016-06-03 23,028 $0.00 23,028 $47.77
Ordinary Shares Stock Option (Right to Buy) Disposition 2016-06-03 35,872 $0.00 35,872 $36.24
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2017-10-29 No 4 M Direct
0 2018-10-27 No 4 M Direct
Footnotes
  1. The price is a weighted average price. These shares were sold in multiple transactions in prices ranging from $82.42 to $82.865, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote in this Form 4.
  2. This balance increased by 261 shares due to exempt transactions such as dividend reinvestment.
  3. These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.